Influenza virus vaccine recombinant Intramuscular and Varilrix Subcutaneous
Determining the interaction of Influenza virus vaccine recombinant Intramuscular and Varilrix Subcutaneous and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.
Professional:The safety and efficacy of concomitant administration of varicella-zoster virus (VZV) vaccine and trivalent inactivated influenza vaccine in adults aged 50 and older were demonstrated in a large randomized, controlled study conducted at 20 sites in the U.S. and Europe. The study compared 382 subjects who received the vaccines simultaneously at separate injection sites (vaccines on day one; placebo at week 4) to 380 subjects who received them sequentially (influenza vaccine and placebo on day one; VZV vaccine at week 4) and found no significant difference in antibody responses between the two groups. Four weeks postvaccination, VZV antibody geometric mean titers were 554 gpELISA units/mL for the concomitant group and 597 gpELISA units/mL for the sequential group. The estimated geometric mean titre ratios (concomitant/sequential) were 0.9 for influenza A (H1N1), 1.1 for influenza A (H3N2), and 0.9 for influenza B according to hemagglutination inhibition assay. Both concomitant and sequential administration were generally well tolerated, with a similar overall incidence of systemic adverse events of approximately 33% and vaccine-related systemic adverse events of approximately 5% within four weeks postvaccination.
- Kerzner B, Murray AV, Cheng E, et al. "Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older." J Am Geriatr Soc 55 (2007): 1499-507
- "Product Information. Zostavax (zoster vaccine live)." Merck & Company Inc, West Point, PA.
Generic Name: influenza virus vaccine, inactivated
Brand name: Afluria, Agriflu, Fluad 2019-2020, Fluarix, Flublok Quadrivalent 2019-2020, Flucelvax, FluLaval, Fluogen, Flushield, Fluvirin, Fluzone, Flucelvax, Fluzone Intradermal Quadrivalent, Fluzone Quadrivalent, Flublok, Flublok Quadrivalent
Synonyms: Influenza virus vaccine (injection), Influenza Virus Vaccine (Inactivated)
Generic Name: zoster vaccine live
Brand name: Zostavax
Synonyms: Zoster vaccine live, Zoster Vaccine (Live/Attenuated)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Influenza virus vaccine recombinant Intramuscular-Varivax
- Influenza virus vaccine recombinant Intramuscular-Varizig
- Influenza virus vaccine recombinant Intramuscular-Varubi
- Influenza virus vaccine recombinant Intramuscular-Varubi (Rolapitant Injection)
- Influenza virus vaccine recombinant Intramuscular-Varubi (Rolapitant Tablets)
- Influenza virus vaccine recombinant Intramuscular-Varubi Intravenous
- Varilrix Subcutaneous-Influenza Virus Vaccine, H5N1
- Varilrix Subcutaneous-Influenza virus vaccine, live Nasal
- Varilrix Subcutaneous-Infugem
- Varilrix Subcutaneous-Infumorph
- Varilrix Subcutaneous-Infumorph injection
- Varilrix Subcutaneous-Infuvite Adult